BACKGROUND The prognosis of gastric cancer in an advanced stage remains poor. The exact efficacy of the use of intraoperative sustained-release chemotherapy with 5-fluorouracil(5-FU) in advanced-stage gastric cancer i...BACKGROUND The prognosis of gastric cancer in an advanced stage remains poor. The exact efficacy of the use of intraoperative sustained-release chemotherapy with 5-fluorouracil(5-FU) in advanced-stage gastric cancer is still unelucidated.AIM To explore the long-term survival benefit of using sustained-release 5-FU implants in stage Ⅱ and stage Ⅲ gastric cancer patients.METHODS Patients with gastric cancer in a locally advanced stage and who underwent an R0 radical resection between Jan 2014, to Dec 2016, in this single institution were included. Patients with pathological diagnoses other than adenocarcinoma were excluded. All included patients were grouped according to whether intraoperative sustained-release(SR) chemotherapy with 5-FU was used or not(NSR). The primary end-point was 5-year overall survival. Kaplan–Meier method with logrank test was used to analyze the overall survival of patients and Cox analysis was used to analyze prognosis factors of these patients.RESULTS In total, there were 563 patients with gastric cancer with locally advanced stage, who underwent an R0 radical resection. 309 patients were included in the final analysis. 219(70.9%) were men, with an average age of 58.25 years. Furthermore, 56(18.1%) received neoadjuvant chemotherapy, and 191(61.8%) were in TNM stage Ⅲ. In addition, 158 patients received intraoperative sustainedrelease chemotherapy with 5-FU and were included in the SR group, while the other 161 patients were included in the NSR group. The overall complication rate was 12.94% in the whole group and 10.81%, 16.46% in SR and NSR groups, respectively. There were no significant differences between the two groups in overall survival and complication rate(P > 0.05). The multivariate cox analysis indicated that only N Stage and neoadjuvant therapy were independent influencing factors of survival.CONCLUSION Intraoperative sustained-release chemotherapy usage with 5-FU, did not improve the survival of patients who underwent an R0 radical resection in locally advanced stage of gastric cancer.展开更多
目的:探讨乳腺癌术中植入缓释氟尿嘧啶进行区域性化疗的安全性及疗效。方法:采用随机对照方法,周一、周三就诊的患者设为对照组(n=26例),周二、周五就诊的患者设为植入组(n=28例),植入组患者在术中植入缓释氟尿嘧啶,比较2组患者术后毒...目的:探讨乳腺癌术中植入缓释氟尿嘧啶进行区域性化疗的安全性及疗效。方法:采用随机对照方法,周一、周三就诊的患者设为对照组(n=26例),周二、周五就诊的患者设为植入组(n=28例),植入组患者在术中植入缓释氟尿嘧啶,比较2组患者术后毒副反应(toxic and side effect)、无病生存率(Disease-free survival rate,DFSR)及总生存率(overall survival rate,OSR)差异。结果:2组患者术后恶心呕吐、脱发、发热等临床毒性反应、血常规、肝肾功能等实验室检查及切口愈合等级比较,差异无统计学意义(P>0.05);2组病例3~12个月DFSR、OSR差异无统计学意义(P>0.05)。结论:2组患者的药物毒副反应、DFSR及OSR无统计学差异,说明乳腺癌术中植入缓释氟尿嘧啶安全可靠,是否可以预防乳腺癌术后局部转移复发、提高无病生存率及总生存率,还有待长期随访。展开更多
基金the CAMS Initiative for Innovative Medicine,No.2016-I2M-1-007。
文摘BACKGROUND The prognosis of gastric cancer in an advanced stage remains poor. The exact efficacy of the use of intraoperative sustained-release chemotherapy with 5-fluorouracil(5-FU) in advanced-stage gastric cancer is still unelucidated.AIM To explore the long-term survival benefit of using sustained-release 5-FU implants in stage Ⅱ and stage Ⅲ gastric cancer patients.METHODS Patients with gastric cancer in a locally advanced stage and who underwent an R0 radical resection between Jan 2014, to Dec 2016, in this single institution were included. Patients with pathological diagnoses other than adenocarcinoma were excluded. All included patients were grouped according to whether intraoperative sustained-release(SR) chemotherapy with 5-FU was used or not(NSR). The primary end-point was 5-year overall survival. Kaplan–Meier method with logrank test was used to analyze the overall survival of patients and Cox analysis was used to analyze prognosis factors of these patients.RESULTS In total, there were 563 patients with gastric cancer with locally advanced stage, who underwent an R0 radical resection. 309 patients were included in the final analysis. 219(70.9%) were men, with an average age of 58.25 years. Furthermore, 56(18.1%) received neoadjuvant chemotherapy, and 191(61.8%) were in TNM stage Ⅲ. In addition, 158 patients received intraoperative sustainedrelease chemotherapy with 5-FU and were included in the SR group, while the other 161 patients were included in the NSR group. The overall complication rate was 12.94% in the whole group and 10.81%, 16.46% in SR and NSR groups, respectively. There were no significant differences between the two groups in overall survival and complication rate(P > 0.05). The multivariate cox analysis indicated that only N Stage and neoadjuvant therapy were independent influencing factors of survival.CONCLUSION Intraoperative sustained-release chemotherapy usage with 5-FU, did not improve the survival of patients who underwent an R0 radical resection in locally advanced stage of gastric cancer.
文摘目的:探讨乳腺癌术中植入缓释氟尿嘧啶进行区域性化疗的安全性及疗效。方法:采用随机对照方法,周一、周三就诊的患者设为对照组(n=26例),周二、周五就诊的患者设为植入组(n=28例),植入组患者在术中植入缓释氟尿嘧啶,比较2组患者术后毒副反应(toxic and side effect)、无病生存率(Disease-free survival rate,DFSR)及总生存率(overall survival rate,OSR)差异。结果:2组患者术后恶心呕吐、脱发、发热等临床毒性反应、血常规、肝肾功能等实验室检查及切口愈合等级比较,差异无统计学意义(P>0.05);2组病例3~12个月DFSR、OSR差异无统计学意义(P>0.05)。结论:2组患者的药物毒副反应、DFSR及OSR无统计学差异,说明乳腺癌术中植入缓释氟尿嘧啶安全可靠,是否可以预防乳腺癌术后局部转移复发、提高无病生存率及总生存率,还有待长期随访。